Semaglutide for Alcohol Use Disorder: Insights from 2026 Lancet RCT
The first large randomized trial finds once-weekly semaglutide reduces heavy drinking days in people with alcohol use disorder and obesity. Here’s what the data mean for you.
Semaglutide for Alcohol Use Disorder: Insights from 2026 Lancet RCT
Featured snippet: A 26-week, double-blind trial published in The Lancet on May 2 2026 found that adults with alcohol use disorder and obesity who received once-weekly semaglutide 2.4 mg, alongside cognitive-behavioral therapy, had 13.7 percentage-points fewer heavy-drinking days than placebo and experienced meaningful weight loss, with mostly mild gastrointestinal side effects.[1]
Last updated August 2026
- Study size: 108 adults with alcohol use disorder (AUD) and body-mass index ≥30 kg/m2[1]
- Dose tested: Semaglutide 2.4 mg subcutaneous once weekly for 26 weeks
- Primary outcome: Change in percentage of heavy-drinking days (≥4 drinks for women, ≥5 for men)
- Key finding: 41.1 % reduction with semaglutide vs 26.4 % with placebo (p = 0.0015)[1]
- Number needed to treat (NNT): 4.3, better than current AUD medicines whose NNT is ≥7[2]
- Status: Semaglutide is not FDA-approved for AUD; any use is off-label
- The 2026 Lancet RCT is the first large, placebo-controlled study to show a clinically significant decline in heavy-drinking days with a GLP-1 receptor agonist.
- Semaglutide achieved an NNT of 4.3, suggesting it could outperform approved AUD drugs such as naltrexone and acamprosate.[2]
- Participants also lost weight and improved metabolic markers, an added benefit for the many people with AUD who have obesity or prediabetes.[3]
- Gastrointestinal side effects were common but generally mild; only one semaglutide patient required hospitalization.[3]
- Regulatory approval will require larger, multisite trials that include people without obesity.
What Did the 2026 Lancet Trial Investigate?
The Copenhagen-based research team asked a straightforward question: can the same GLP-1 receptor agonist that curbs appetite also dial down alcohol consumption? They enrolled 108 adults (40 % women, mean age 42) who met DSM-5 criteria for moderate-to-severe AUD and had a BMI of at least 30 kg/m2.[1] Participants were randomly assigned to semaglutide 2.4 mg or placebo for 26 weeks, while all received standardized cognitive-behavioral therapy (CBT). Heavy-drinking days — defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) threshold — served as the primary endpoint.
How Was Semaglutide Dosed in the Study?
Investigators followed the same titration schedule used for FDA-approved weight-management indications. Weekly doses escalated from 0.25 mg to 2.4 mg over 16 weeks, then remained at 2.4 mg until week 26. Adherence exceeded 90 % based on vial counts and electronic diaries.[1] All injections were given at the clinic to maintain blinding.
What Were the Main Alcohol-Related Outcomes?
By week 26, semaglutide recipients had a 41.1-percentage-point drop in heavy-drinking days from baseline, compared with 26.4 points in the placebo group — the adjusted treatment difference of −13.7 points was statistically and clinically significant (p = 0.0015).[1]
| Outcome | Semaglutide (n = 54) | Placebo (n = 54) | Between-group Δ (95 % CI) |
|---|---|---|---|
| Heavy-drinking days (% of days/month) | −41.1 | −26.4 | −13.7 (−22.0 to −5.4) |
| Total drinks per month | −52 ± 18 | −31 ± 17 | −21 (−28 to −14) |
| Penn Alcohol Craving Scale | −6.4 points | −3.1 points | −3.3 (−4.8 to −1.9) |
Did Participants Also Lose Weight?
Yes. Although weight loss was a secondary outcome, it mirrors findings from obesity studies. According to the NIH summary of the trial, body weight, waist circumference, and hemoglobin A1c all declined more with semaglutide than with placebo.[3] Earlier, smaller trials reported about a 5 % mean weight reduction after nine weeks of lower-dose semaglutide.[4]
| Metabolic Measure | Baseline Mean | Change with Semaglutide | Change with Placebo |
|---|---|---|---|
| Body weight (kg) | 99.2 | −7.4 kg | −2.1 kg |
| Waist circumference (cm) | 113 | −6.8 | −1.9 |
| HbA1c (%) | 5.8 | −0.3 | −0.1 |
How Might Semaglutide Reduce Alcohol Cravings?
Animal and human neuroimaging studies suggest GLP-1 receptors in the mesolimbic “reward” pathway modulate dopamine release linked to craving.[5] By activating those receptors, semaglutide may blunt the reinforcing effects of alcohol, similar to how it dampens appetite for high-calorie foods. The Lancet authors also found an inverse correlation between weight loss and heavy-drinking days (Spearman ρ = −0.40), hinting that metabolic improvements could indirectly support reduced alcohol use.[1]
Is Semaglutide Approved for Alcohol Use Disorder?
No. In the United States, semaglutide holds FDA approvals for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction.[6] Using it for AUD is considered off-label. Physicians may legally prescribe off-label when supported by evidence, but insurers seldom cover the cost for non-approved indications, and long-term safety in people without obesity remains unproven.
Who Might Benefit — and Who Should Avoid Off-Label Use?
If you live with AUD and obesity, have tried first-line medications (naltrexone, acamprosate, disulfiram) without success, and tolerate GLP-1 drugs, you could be a candidate for off-label semaglutide. On the other hand, people with a history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal disease should avoid GLP-1 therapy, per the semaglutide prescribing information.
Not sure which path is right for you? Use this mini-guide:
- I prefer oral therapy. Discuss acamprosate or oral naltrexone with your clinician.
- I need weight loss plus AUD control. Ask whether GLP-1 therapy could address both goals.
- I have contraindications to GLP-1s. Explore monthly injectable naltrexone or behavioral options.
- I’m new to treatment. A first appointment guided by our question checklist for doctors can clarify choices.
When to Contact Your Healthcare Provider
- Severe or persistent nausea, vomiting, or abdominal pain
- Signs of pancreatitis (mid-back pain, fever, rapid heartbeat)
- Sudden changes in vision or severe dehydration
- Thoughts of self-harm or worsening depression
- Allergic reactions such as rash, swelling, or difficulty breathing
Scientific References
- Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687-1698. PMID 42070571.
- National Institutes of Health. Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking. News release, April 30 2026.
- Doctrow B. GLP-1 plus therapy can reduce heavy drinking. NIH Research Matters. May 12 2026.
- Stanley B, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Netw Open. 2025;8(4):e2511323. PMID 39937469.
- Zhu J, et al. GLP-1 receptor agonists for treating alcohol use disorder: a critical review. BMJ. 2025;380:e072345.
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. Accessed August 2026.
Source: FDA-approved prescribing information for semaglutide (Wegovy)
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
